Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OMED OncoMed Pharmaceuticals		$0.89	$0.55 ▼ $3.35	$34.43M	1.86	768,904 shs	1,201 shs
OSTX OS Therapies	$2.26 -9.6%	$1.87	$1.12 ▼ $7.00	$72.08M	N/A	742,500 shs	834,236 shs
VIRI Virios Therapeutics	$4.65 -6.8%	$4.84	$0.13 ▼ $1.04	$89.55M	1.58	1.05 million shs	27,858 shs
WHWK Whitehawk Therapeutics	$1.77 -2.2%	$1.82	$1.39 ▼ $3.81	$85.30M	0.55	98,711 shs	145,185 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OMED OncoMed Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
OSTX OS Therapies	+7.30%	+14.16%	+38.89%	+58.23%	-38.12%
VIRI Virios Therapeutics	-1.38%	+3.74%	+4.61%	-12.46%	+2,309.46%
WHWK Whitehawk Therapeutics	0.00%	+9.70%	0.00%	+180,999,900.00%	+180,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
OMED OncoMed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	2.2006 of 5 stars	3.6	0.0	0.0	0.0	2.4	0.8	0.6
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
OMED OncoMed Pharmaceuticals	0.00	N/A	N/A	N/A
OSTX OS Therapies	3.25	Buy	$18.00	696.46% Upside
VIRI Virios Therapeutics	2.00	Hold	$5.00	7.53% Upside
WHWK Whitehawk Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest OMED, VIRI, WHWK, and OSTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/20/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/11/2025	WHWK Whitehawk Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
8/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/14/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/30/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
OMED OncoMed Pharmaceuticals	$44.42M	0.00	N/A	N/A	$1.25 per share	0.00
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	$0.20 per share	N/A
WHWK Whitehawk Therapeutics	$25.98M	3.21	N/A	N/A	$3.65 per share	0.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
OMED OncoMed Pharmaceuticals	-$8.10M	-$0.16	N/A	N/A	N/A	-18.24%	-13.14%	-7.73%	N/A
OSTX OS Therapies	-$7.79M	-$0.79	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A
VIRI Virios Therapeutics	-$5.30M	-$0.27	N/A	N/A	N/A	N/A	-130.33%	-115.00%	N/A
WHWK Whitehawk Therapeutics	-$63.69M	-$0.06	0.00	∞	N/A	99.42%	-75.99%	-68.57%	N/A

Latest OMED, VIRI, WHWK, and OSTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	WHWK Whitehawk Therapeutics	$0.49	-$0.76	-$1.25	-$0.76	$100.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
OMED OncoMed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
OMED OncoMed Pharmaceuticals	N/A	5.04	5.04
OSTX OS Therapies	N/A	0.76	0.76
VIRI Virios Therapeutics	N/A	7.27	7.27
WHWK Whitehawk Therapeutics	N/A	20.41	20.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
OMED OncoMed Pharmaceuticals	45.16%
OSTX OS Therapies	N/A
VIRI Virios Therapeutics	9.05%
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
OMED OncoMed Pharmaceuticals	20.32%
OSTX OS Therapies	13.80%
VIRI Virios Therapeutics	12.20%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
OMED OncoMed Pharmaceuticals	22	38.69 million	N/A	Optionable
OSTX OS Therapies	N/A	31.89 million	N/A	N/A
VIRI Virios Therapeutics	5	19.26 million	16.91 million	Optionable
WHWK Whitehawk Therapeutics	40	47.13 million	23.61 million	N/A

OMED, VIRI, WHWK, and OSTX Headlines

Recent News About These Companies

Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Misses Expectations By $1.25 EPS

August 10, 2025 | marketbeat.com

Whitehawk Therapeutics (NASDAQ:WHWK) Downgraded to "Strong Sell" Rating by Wall Street Zen

August 10, 2025 | marketbeat.com

Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

August 7, 2025 | prnewswire.com

Whitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 22, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMED, VIRI, WHWK, and OSTX Company Descriptions

OncoMed Pharmaceuticals NASDAQ:OMED

OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors; and Phase Ib clinical trials for patients with second-line metastatic colorectal cancer, as well as in Phase Ib clinical trial in patients with platinum-resistant ovarian cancer. The company is also developing Etigilimab (Anti-TIGIT, OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia/b clinical trials for patients with advanced or metastatic solid tumors. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California.

OS Therapies NYSE:OSTX

$2.26 -0.24 (-9.60%)

Closing price 04:00 PM Eastern

Extended Trading

$2.25 -0.01 (-0.44%)

As of 07:59 PM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Virios Therapeutics NASDAQ:VIRI

$4.65 -0.34 (-6.81%)

As of 08/27/2025

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Whitehawk Therapeutics NASDAQ:WHWK

$1.77 -0.04 (-2.21%)

As of 04:00 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time